New insights in KRAS mutation

Dr. Miriam Molina-Arcas
Francis Crick Institute, London (UK)

Resistance pathways to RAS inhibition

Dr. Rafael Rosell
Instituto Oncológico Dr Rosell, Barcelona

BRAF mutations: Small changes, big impact

Dr. Joaquim Bosch
ICO, Hospital Univ. Dr. Josep Trueta, Girona

HER2: A new frontier in precision oncology

Dr. Ernest Nadal
ICO, Hospital Duran i Reynals, L'Hospitalet de Llobregat, Barcelona

Fusions in lung cancer

Dr. Rosario García Campelo
Hospital Univ. de A Coruña

Discussion

Poster 14: Plasmatic CXCL13 as a biomarker of primary resistance to immunotherapy in non-small cell lung cancer

Dr. Marta Molina-Alejandre
Hospital Univ. Puerta de Hierro, Majadahonda, Madrid

Poster 21: Liquid Biopsy: The future of surveillance after curative resection of non-small cell lung cancer?

Dr. Eider Azkona
Hospital Univ. de Cruces, Barakaldo

Poster 35: Circulating low density neutrophils as a major mechanismof resistance to first line anti-pd1/pd-l1 immunotherapy in non-small cell lung cancer

Dr. Natalia Castro
Clinica Univ. de Navarra, Pamplona

Poster 52: Circulating tumor DNA as a prognostic and dynamic biomarker in unresectable stage III NSCLC

Dr. Nil Navarro
Hospital del Mar, Barcelona

Poster 61: KRAS G12C vs. NON-G12C: Divergent immunotherapy outcomes in non-small cell lung cancer

Dr. Clàudia Miquel
Hospital del Mar, Barcelona

Poster 63: Neoadjuvant chemo-immunotherapy in non-small cell lung cancer: The hidden value of the lung immune prognostic index (LIPI)

Dr. Karla Medina
Hospital Univ. Ntra. Sra. de Candelaria, Santa Cruz de, Tenerife

Treating resistance mechanisms in oncogenic diseases

Dr. Óscar Juan-Vidal
Hospital Univ. y Politécnico La Fe, Valencia

Is the future conjugated? ADCs in lung cancer treatment

Dr. Francesca Fusco
IRCCS - Istituto Nazionale Tumori Regina Elena, Rome (Italy)

Bispecific antibodies: BITES/TRITES

Dr. Biagio Ricciuti
Dana-Farber Cancer Institute, Boston (USA)

Other immunotherapy strategies: Vaccines, cellular therapy, oncolytic virus

Dr. Enriqueta Felip
Hospital Univ. Vall d'Hebron, Barcelona

Discussion

Changing landscape in SCLC limited disease

Dr. Anna Estival
Hospital Univ. Insular de Gran Canaria, Las Palmas

New strategies in SCLC metastatic disease

Dr. Edurne Arriola
Hospital del Mar, Barcelona

Large cell neuroendocrine new insights

Dr. Noemí Reguart
Hospital Clínic Barcelona

Systemic treatment in mesothelioma

Dr. Bartomeu Massutí
Hospital General Univ. Dr. Balmis, Alicante

Discussion

How to choose immunotherapy agent/s in first line

Dr. Martín Lázaro
Complejo Hospitalario Univ. de Vigo

Microbiota role in immunotherapy efficacy

Dr. Laurence Zitvogel
Institut Gustave-Roussy, Villejuif (France)

Optimization of IO treatment: Administration schedule, circadian rhythms...

Dr. Sergio Vázquez
Hospital Univ. Lucus Augusti, Lugo

Consolidation RT in metastatic disease without oncogenic driver

Dr. Amelia Insa
Hospital Clínico Univ. de Valencia

Discussion